Gaithersburg, MD, United States of America

Melissa Marie Damschroder

This inventor holds 26 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Antibody Engineering. Top assignees: Medimmune Limited, Boston Pharmaceuticals, Inc., Humabs Biomed Sa. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Melissa Marie Damschroder. Retrieved from https://idiyas.com/inventor/melissa-marie-damschroder

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 14)

% Patents Active = 96.2

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 7.2

ph-index = 7

Forward Citations = 144(Granted Patents)

Location History:

Germantown, MD (US) (2011 - 2014)
Gaithersburg, MD (US) (2016 - 2023)

Company Filing History:

Boston Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Binding Molecules

CD73

Antibodies

IL-21

Pseudomonas

Cancer Treatment

Humanized Antibodies

OX40

Fusion Proteins

Hinge Domain Engineering

Combination Therapies

Leukotoxins

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630648 - BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF (2026-05-19),

2. 12428473 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2025-09-30),

3. 11673950 - ILT7 binding molecules and methods of using the same (2023-06-13),

4. 11578119 - Antibodies directed againstleukotoxins (2023-02-14),

5. 11529415 - Antibodies specific for IL-21 and uses thereof (2022-12-20),

6. 11525012 - Binding molecules specific for CD73 and uses thereof (2022-12-13),

7. 11203633 - Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv (2021-12-21),

8. 11168133 - Combinations of anti-antibodies (2021-11-09),

9. 11072652 - ILT7 binding molecules and methods of using the same (2021-07-27),

10. 11059884 - Antibodies directed againstleukotoxins (2021-07-13),

11. 10597439 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2020-03-24),

12. 10588969 - Antibodies specific for IL-21 and uses thereof (2020-03-17),

13. 10556968 - Binding molecules specific for CD73 and uses thereof (2020-02-11),

14. 10287362 - Binding molecules specific for CD73 and uses thereof (2019-05-14),

15. 10160812 - Bispecific HER2 antibodies (2018-12-25),

Title: **Melissa Marie Damschroder: Innovator in Biotherapeutics**

Introduction

Melissa Marie Damschroder is a distinguished inventor based in Gaithersburg, MD, recognized for her substantial contributions to the field of biotherapeutics. With an impressive portfolio of 24 patents, her work primarily focuses on novel binding molecules and methods that address critical health challenges.

Latest Patents

Among her recent innovations are two notable patents:

1. **ILT7 Binding Molecules and Methods of Using the Same** - This invention is aimed at ILT7 binding molecules, including anti-ILT7 antibodies. It offers potential methods for treating or preventing autoimmune diseases associated with ILT7-expressing cells.

2. **Antibodies Directed Against Leukotoxins** - This patent discloses leukotoxin-binding antibodies and their antigen-binding fragments. These antibodies can be utilized to detect leukotoxins and serve in therapeutic methods for preventing infections.

Career Highlights

Damschroder has built a significant career, working with renowned companies such as MedImmune Limited and Boston Pharmaceuticals, Inc. Her expertise in developing innovative therapies has made her a valuable asset in these organizations.

Collaborations

Throughout her career, Melissa has collaborated with notable colleagues, including Qun Du and Scott A Hammond. These partnerships have contributed to her successful patent applications and advancements in her field.

Conclusion

Melissa Marie Damschroder exemplifies the spirit of innovation in the biotherapeutics sector, with her patents paving the way for new treatment strategies against significant health issues. Her achievements reflect her dedication to improving healthcare outcomes through scientific discovery and collaboration.

Profile summary based on public USPTO records.